All News
Filter News
Found 68 articles
-
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
-
Organicell To Present Results Of Zofin™ Clinical Studies At The International Society Of Cell And Gene Therapy Annual Meeting
5/25/2021
Organicell To Present Results Of Zofin ™ Clinical Studies At The International Society Of Cell And Gene Therapy Annual Meeting
-
Organicell Signs an Exclusive Distribution Agreement with Apex Services in Pakistan
5/19/2021
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has signed an exclusive distribution agreement with Apex Services Pakistan to import and distribute Zofin TM to hospitals and clinics in the country.
-
Organicell Receives Approval in Pakistan for the Use of Zofin™ for Compassionate Grounds for COVID-19
5/11/2021
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced its Zofin™ therapy has been approved by Pakistani regulators to be used for a COVID-19 patient on compassionate grounds.
-
Organicell Begins Up-Listing Process On NASDAQ Exchange
5/4/2021
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it is currently exploring options to up-list its common stock to the NASDAQ Capital Market tier of the NASDAQ Stock Market, LLC.
-
Clinical Catch-Up: April 26-30
5/3/2021
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications. -
Organicell Announces Positive Results of Initial COVID-19 Zofin™ Patient Trial in India and Trial Expansion
4/28/2021
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India.
-
Clinical Catch-Up: April 19-23
4/26/2021
It was a busy week for non-COVID-19-related clinical trial news, while fairly quiet on the COVID-19 arena. Here’s a look. -
Organicell Completes Enrollment for its Expanded Access Trial to Treat COVID-19 Patients with Zofin™
4/22/2021
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the company has completed enrollment for its U.S. Food and Drug Administration (FDA) granted expanded access trial for Zofin for the treatment of COVID-19.
-
Organicell Announces FDA Approval Of IND Application For The Use Of Zofin™ In The Treatment Of Osteoarthritis
4/21/2021
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of knee osteoarthritis.
-
Organicell and Oklahoma State University Enter Into Agreement To Study Zofin™ in Respiratory Diseases Caused By Virus Infections Of Pandemic Potential
4/14/2021
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into an agreement with Oklahoma State University to evaluate Zofin™ for the treatment of respiratory diseases caused by virus infections of pandemic potential.
-
Two financings – and a surprise stock bump – in three days for the some of the most advanced extracellular vesicle (EV) companies show investors are champing at the bit to see the technology unleashed.
-
Organicell and The Centers for Disease Control and Prevention Enter Into Agreement To Conduct Research on Influenza Viruses of Pandemic Potential
3/23/2021
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into a Material Cooperative Research and Development Agreement with the Centers for Disease Control and Prevention (“CDC”) to determine the anti-inflammatory and anti-infective effectiveness of Zofin™ in experimental models of influenza
-
‘Frontiers in Medicine’ Publishes Organicell’s Case Report Demonstrating the Use of Zofin™ in the Treatment of COVID-19 Patients
3/18/2021
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced the publication of a peer-reviewed case report analyzing the clinical outcomes of Zofin treatment in three critically ill patients suffering from severe, multi-organ complications induced by COVID-19 infection.
-
While the space is just beginning to emerge, therapies for long-haul COVID-19 patients are still very much an unmet need.
-
Clinical Catch-Up: January 25-29
2/1/2021
It was a busy week for clinical trial news. Read on for more information. -
The FDA is on a roll granting approvals. Three companies announced IND updates today.
-
Organicell Announces FDA Approval of IND Application for the Use of Zofin™ in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
1/28/2021
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of patients diagnosed with chronic obstructive pulmonary disease (COPD).
-
The Forgotten Ones. Will Long-Haulers Be the Next Public Health Crisis?
1/12/2021
Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, will host a live online discussion on the topic of COVID-19 long-haulers on Wednesday, January 13th at 7 P.M. EST.
-
Organicell Regenerative Medicine and Its Investigational Therapeutic Zofin™ Featured in Two National Publications Examining Potential Therapies for COVID-19 Long-Haulers
12/29/2020
Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR) (the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies today announced that the Company and its therapeutic drug Zofin™ were recently featured in articles in both the Wall Street Journal and BioSpace, which examined potential therapies for COVID-19 long-haulers.